LGND heads into the week at $319.43 with a striking split: the Street just raised its price target to a 52-week high while short sellers have quietly doubled their position over the past month.
The tension between analyst conviction and short-seller activity is the defining feature of the setup right now. Stifel raised its target this morning from $255 to $332 — a 30% lift — while maintaining a Buy rating, pushing the mean price target to $285. That target now sits below the current price, which means even the bull camp's updated numbers trail where the stock is trading. The direction of travel on the Street is unambiguously positive: every analyst action over the past several months has been a raise, with Citi, RBC Capital, HC Wainwright, Oppenheimer, and BofA (which initiated coverage in March) all lifting targets through the spring. None have downgraded. But the mean target of $285 against a $319 close suggests the consensus has struggled to keep pace with a stock that has rallied 35% in a single month.
Short interest tells a very different story to the analyst optimism. Bears have been adding aggressively — SI has climbed nearly 60% over the past month and now accounts for 15.9% of the free float, a level that counts as genuinely elevated. The one-week build alone was 5.9%, with another 6.5% jump on Tuesday. The ORTEX short score has risen to 73.4, its highest reading in the data window. Yet the borrow market is not yet flashing stress. Cost to borrow is running at just 0.51% — effectively free — and availability, while tightening, remains at roughly 203% of short interest, meaning there are still more than two shares available to borrow for every one currently lent out. The borrow pool has tightened sharply from the 390–430% range seen in early June, but it is still far from squeezed. That combination — rapidly building short interest against loose borrow conditions — points to a deliberate bear thesis rather than a forced or opportunistic short.
Options positioning corroborates the bullish lean on the other side of the ledger. The put/call ratio is near its 52-week low at 0.059, almost a full standard deviation below its 20-day average of 0.24. Call volume is dominant. That reads as the options market skewing heavily toward upside exposure — a direct counterpoint to the growing short book. The valuation backdrop adds context: the trailing PE has expanded to 27x, up about four turns over the past month, reflecting the price run rather than any earnings re-rating. EPS surprise ranks in just the 5th percentile of the universe, a notable weak spot, and the 12-month forward EPS growth score sits in the bottom quintile. Bears appear to be anchored on that disconnect between price momentum and fundamental delivery.
Insider activity has run net positive in nominal terms over 90 days, but the recent picture is less clean. The CLO, Andrew Reardon, sold approximately $1.57m worth of shares across multiple tranches on July 1, at prices between $310 and $318. A director sold $765k in mid-June. These are modest in scale relative to the company and carry low significance scores, but the direction is worth noting given the broader setup.
The next test is Q2 earnings on August 7. The last print triggered a 4.8% one-day decline and a 5.8% five-day decline — the only historical reaction in the dataset, which limits how much weight to put on it. What to watch between now and then: whether the borrow availability continues to tighten as short interest builds, and whether the Street's relentless target-raising cycle can finally close the gap to a price that has already run well past consensus.
See the live data behind this article on ORTEX.
Open LGND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
